Clinical Trial Update: the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 clinical trial evaluating the safety and efficacy of a targeted BCMA in vivo lentiviral vector injection for recurrent or refractory autoimmune…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Idiopathic Inflammatory Myopathy
• Igg4-related Disease
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• BCMA-targeted in vivo lentiviral vector (BCMA-targeted in vivo lentiviral vector)

Snippet

Sponsor: Tongji Hospital | Conditions: Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases | EARLY_Phase 1 | Status: RECRUITING